Imaging Diagnostic Systems (IDS) gets investigational device exemption (IDE) for CT-M (computed tomography laser mammography):
This article was originally published in Clinica
Executive Summary
Imaging Diagnostic Systems (US) has received FDA permission to start a trial of its computed tomography laser mammography system. The IDS system uses a high power diode-pumped continuous visible laser to produce sharp, three-dimensional, cross-sectional images without the need for breast compression devices. The company predicts sales of $5 million this year in Europe, the Middle and Far East and US trial sites.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.